NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
Clinical Trials
11 trialsNCT03899805 2025-08-28
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03840772 2024-09-20
ERASING
Italian Sarcoma Group
Phase 2 Completed
NCT01327885 2023-06-22
Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Eisai Inc.
Phase 3 Completed
NCT03441360 2022-10-05
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Eisai Inc.
Phase 2 Completed
NCT03245450 2022-06-28
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03810976 2022-06-16
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Yonsei University
Phase 2 Completed
NCT02097238 2020-05-19
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03058406 2020-04-06
HAL03T
Eisai Inc.
Completed
NCT02014337 2018-01-17
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Corcept Therapeutics
Phase 1 Completed
NCT00413192 2017-04-26
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
Eisai Inc.
Phase 2 Completed